Cysteine accessibility analysis of the human alpha7 nicotinic acetylcholine receptor ligand-binding domain identifies L119 as a gatekeeper
about
The binding orientation of epibatidine at α7 nACh receptorsα7β2 nicotinic acetylcholine receptors assemble, function, and are activated primarily via their α7-α7 interfaces.Nicotine: specific role in angiogenesis, proliferation and apoptosis.The duplicated α7 subunits assemble and form functional nicotinic receptors with the full-length α7.Tethered agonist analogs as site-specific probes for domains of the human α7 nicotinic acetylcholine receptor that differentially regulate activation and desensitization.The effective opening of nicotinic acetylcholine receptors with single agonist binding sitesAn Accessory Agonist Binding Site Promotes Activation of α4β2* Nicotinic Acetylcholine Receptors.Critical Molecular Determinants of α7 Nicotinic Acetylcholine Receptor Allosteric Activation: SEPARATION OF DIRECT ALLOSTERIC ACTIVATION AND POSITIVE ALLOSTERIC MODULATION.An unusual pattern of ligand-receptor interactions for the α7 nicotinic acetylcholine receptor, with implications for the binding of varenicline.The activity of GAT107, an allosteric activator and positive modulator of α7 nicotinic acetylcholine receptors (nAChR), is regulated by aromatic amino acids that span the subunit interface.Unorthodox Acetylcholine Binding Sites Formed by α5 and β3 Accessory Subunits in α4β2* Nicotinic Acetylcholine Receptors.Persistent activation of α7 nicotinic ACh receptors associated with stable induction of different desensitized states.Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors.Calcium imaging with genetically encoded sensor Case12: Facile analysis of α7/α9 nAChR mutants.Non-equivalent ligand selectivity of agonist sites in (α4β2)2α4 nicotinic acetylcholine receptors: a key determinant of agonist efficacy.
P2860
Q33561991-355F6345-D47A-475D-8446-7155FB0E09F4Q34062025-326D4CAA-EFD0-4760-9FAA-617D12072663Q34229828-F857736C-B3CD-4E1D-B98D-3932B183B46DQ34249085-F8E4DBCD-AEDC-40A9-9DA4-EA9ADE65B178Q34359550-F5D7DA30-B419-4E7B-AC88-862A8FAE5661Q34745010-D8129ACC-9AC6-40B7-A8A7-F1539A4E3B92Q35662305-AB42D47F-96B2-41AA-A384-429BB24A14EDQ36650296-EC1120A8-057F-4E44-A7B5-A16E16385806Q37027040-DA692E75-639D-4BCB-A4EB-D27ED8E595EFQ37583624-68E7BAF4-14D6-4259-999D-C687A749D799Q38435927-8A45E681-648F-4BF0-96FF-91958A959844Q38801002-C372FB52-3F36-463A-9314-930E8A170776Q39136644-3CC45E46-9707-4AA1-84EE-A5950CFD1992Q41349051-E29F82DF-938E-4495-B744-AFDC1E1336A7Q41848168-54A5C80B-5940-41FE-9A6A-CFB36D31404E
P2860
Cysteine accessibility analysis of the human alpha7 nicotinic acetylcholine receptor ligand-binding domain identifies L119 as a gatekeeper
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cysteine accessibility analysi ...... dentifies L119 as a gatekeeper
@ast
Cysteine accessibility analysi ...... dentifies L119 as a gatekeeper
@en
Cysteine accessibility analysi ...... dentifies L119 as a gatekeeper
@nl
type
label
Cysteine accessibility analysi ...... dentifies L119 as a gatekeeper
@ast
Cysteine accessibility analysi ...... dentifies L119 as a gatekeeper
@en
Cysteine accessibility analysi ...... dentifies L119 as a gatekeeper
@nl
prefLabel
Cysteine accessibility analysi ...... dentifies L119 as a gatekeeper
@ast
Cysteine accessibility analysi ...... dentifies L119 as a gatekeeper
@en
Cysteine accessibility analysi ...... dentifies L119 as a gatekeeper
@nl
P2093
P2860
P1433
P1476
Cysteine accessibility analysi ...... dentifies L119 as a gatekeeper
@en
P2093
Clare Stokes
Dustin K Williams
Jingyi Wang
Nicole A Horenstein
Roger L Papke
P2860
P304
P356
10.1016/J.NEUROPHARM.2010.07.014
P577
2010-07-27T00:00:00Z